← Literature

Targeting the incretin system in obesity and type 2 diabetes mellitus.

review • 2024 • ID: 38632474

Moderate Confidence Review

Primary source: [Open]

Linked compounds: semaglutidetirzepatideretatrutideliraglutide

Outcomes summary

Review summarizing the incretin system (including GLP-1 and GIP biology) and how incretin-based therapies are leveraged in obesity and type 2 diabetes.

Limitations

Review article; interpretation depends on included evidence and is not a substitute for individual trial data.

Notes

Primary source: PMID 38632474 (see PubMed link on this page).